Suppr超能文献

耗竭的 CD8 T 细胞亚群在肿瘤微环境中扩增并抑制癌症免疫治疗。

A Burned-Out CD8 T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy.

机构信息

Department of Immunobiology, Yale University, New Haven, Connecticut.

Division of Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.

出版信息

Cancer Discov. 2021 Jul;11(7):1700-1715. doi: 10.1158/2159-8290.CD-20-0962. Epub 2021 Mar 3.

Abstract

Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non-small cell lung cancer (NSCLC). We identified a burned-out CD8 TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8 TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance. SIGNIFICANCE: We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8 tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker..

摘要

肿瘤浸润淋巴细胞(TIL)功能失调的具体机制仍知之甚少。在这里,我们采用了一种双管齐下的方法,使用单细胞质谱流式细胞术和组织成像技术从 25 名可切除和 35 名晚期非小细胞肺癌(NSCLC)患者中分离 TIL。我们鉴定了一种功能失调的耗尽型 CD8 TIL 亚群(Ebo),该亚群特异性地在肿瘤微环境(TME)中积累,但不在相邻的非肿瘤组织中积累。Ebo 表现出最高的增殖和激活标志物表达,但产生的 IFNγ 最少,是最凋亡的 CD8 TIL 亚群。使用人源化患者来源的肿瘤异种移植模型,我们证明 Ebo 的扩增发生在 PD-1/B7-H1 通路依赖性的 TME 内。基线肿瘤组织中 Ebo 的丰度与 NSCLC 患者对抗 PD 治疗的耐药性相关。我们的研究鉴定了一种功能失调的 TIL 亚群,与先前描述的耗竭性 T 细胞具有不同的特征,并暗示了克服免疫治疗耐药性的策略。意义:我们鉴定了一种高度增殖、过度激活和凋亡的功能失调的 CD8 肿瘤浸润亚群,与先前描述的耗竭性 T 细胞在功能上不同。该群体在 PD-1/B7-H1 依赖性方式在肺癌组织中扩增,其丰度与癌症免疫治疗的耐药性相关,因此成为一种潜在的组织生物标志物。

相似文献

1
A Burned-Out CD8 T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy.
Cancer Discov. 2021 Jul;11(7):1700-1715. doi: 10.1158/2159-8290.CD-20-0962. Epub 2021 Mar 3.
3
Dynamic changes in PD-L1 expression and CD8 T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
Lung Cancer. 2019 Oct;136:30-36. doi: 10.1016/j.lungcan.2019.07.027. Epub 2019 Aug 1.
8
Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
J Egypt Natl Canc Inst. 2018 Dec;30(4):125-131. doi: 10.1016/j.jnci.2018.08.003. Epub 2018 Oct 15.
10
Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.
Bosn J Basic Med Sci. 2020 Aug 3;20(3):329-335. doi: 10.17305/bjbms.2019.4474.

引用本文的文献

2
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
Nat Rev Clin Oncol. 2025 Aug 14. doi: 10.1038/s41571-025-01061-7.
3
T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation.
Front Immunol. 2025 May 29;16:1604310. doi: 10.3389/fimmu.2025.1604310. eCollection 2025.
4
The tumor microenvironment of non-small cell lung cancer impairs immune cell function in people with HIV.
J Clin Invest. 2025 Jun 3;135(14). doi: 10.1172/JCI177310. eCollection 2025 Jul 15.
5
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.
Nat Rev Clin Oncol. 2025 May 16. doi: 10.1038/s41571-025-01021-1.
7
The diversity of CD8 T cell dysfunction in cancer and viral infection.
Nat Rev Immunol. 2025 Apr 11. doi: 10.1038/s41577-025-01161-6.
8
Advancing the understanding of the role of apoptosis in lung cancer immunotherapy: Global research trends, key themes, and emerging frontiers.
Hum Vaccin Immunother. 2025 Dec;21(1):2488074. doi: 10.1080/21645515.2025.2488074. Epub 2025 Apr 5.
10
Cross-Talk Between Cancer and Its Cellular Environment-A Role in Cancer Progression.
Cells. 2025 Mar 10;14(6):403. doi: 10.3390/cells14060403.

本文引用的文献

1
The single-cell pathology landscape of breast cancer.
Nature. 2020 Feb;578(7796):615-620. doi: 10.1038/s41586-019-1876-x. Epub 2020 Jan 20.
2
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11.
3
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8 T Cells.
Cancer Cell. 2019 Dec 9;36(6):613-629.e7. doi: 10.1016/j.ccell.2019.10.006. Epub 2019 Nov 21.
4
Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors.
Br J Cancer. 2019 Nov;121(11):979-982. doi: 10.1038/s41416-019-0616-1. Epub 2019 Oct 31.
6
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.
7
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Immunity. 2019 Feb 19;50(2):477-492.e8. doi: 10.1016/j.immuni.2019.01.006. Epub 2019 Feb 5.
8
High-Parameter Single-Cell Analysis.
Annu Rev Anal Chem (Palo Alto Calif). 2019 Jun 12;12(1):411-430. doi: 10.1146/annurev-anchem-061417-125927. Epub 2019 Jan 30.
10
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1CD8 Tumor-Infiltrating T Cells.
Immunity. 2019 Jan 15;50(1):181-194.e6. doi: 10.1016/j.immuni.2018.11.014. Epub 2019 Jan 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验